相似文献
1
New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a030478. doi: 10.1101/cshperspect.a030478.
2
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2019 Mar;75(3):368-373. doi: 10.1016/j.eururo.2018.09.049. Epub 2018 Oct 26.
3
Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Horm Cancer. 2014 Oct;5(5):265-73. doi: 10.1007/s12672-014-0190-1. Epub 2014 Jul 22.
4
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Nat Rev Urol. 2016 Dec;13(12):697-698. doi: 10.1038/nrurol.2016.212. Epub 2016 Nov 2.
5
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.
Oncogene. 2015 Apr 2;34(14):1745-57. doi: 10.1038/onc.2014.115. Epub 2014 May 19.
6
Androgen pathway resistance in prostate cancer and therapeutic implications.
Expert Opin Pharmacother. 2015;16(10):1521-37. doi: 10.1517/14656566.2015.1055249. Epub 2015 Jun 12.
7
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8.
8
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
J Steroid Biochem Mol Biol. 2015 Sep;153:105-13. doi: 10.1016/j.jsbmb.2015.05.010. Epub 2015 May 29.
9
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Med Oncol. 2016 May;33(5):44. doi: 10.1007/s12032-016-0759-3. Epub 2016 Apr 4.
10
Targeting extra-gonadal androgens in castration-resistant prostate cancer.
J Steroid Biochem Mol Biol. 2015 Jan;145:157-63. doi: 10.1016/j.jsbmb.2014.09.006. Epub 2014 Sep 22.
引用本文的文献
1
RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer.
Int J Mol Sci. 2025 Jun 6;26(12):5463. doi: 10.3390/ijms26125463.
2
Updates on SPOP Gene Mutations in Prostate Cancer and Computational Insights From TCGA cBioPortal Database.
Scientifica (Cairo). 2025 May 20;2025:4084224. doi: 10.1155/sci5/4084224. eCollection 2025.
3
Inceptor correlates with markers of prostate cancer progression and modulates insulin/IGF1 signaling and cancer cell migration.
Mol Metab. 2023 May;71:101706. doi: 10.1016/j.molmet.2023.101706. Epub 2023 Mar 15.
4
BMX controls 3βHSD1 and sex steroid biosynthesis in cancer.
J Clin Invest. 2023 Jan 17;133(2):e163498. doi: 10.1172/JCI163498.
5
Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.
Comput Math Methods Med. 2022 May 31;2022:2147763. doi: 10.1155/2022/2147763. eCollection 2022.
6
Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.
Cancer Lett. 2021 Apr 28;504:49-57. doi: 10.1016/j.canlet.2021.01.029. Epub 2021 Feb 4.
7
Epigenetic modification-dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells.
Cancer Sci. 2021 Feb;112(2):691-702. doi: 10.1111/cas.14731. Epub 2020 Dec 7.
8
Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer.
Cancers (Basel). 2020 May 28;12(6):1385. doi: 10.3390/cancers12061385.
9
Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Molecules. 2020 May 24;25(10):2448. doi: 10.3390/molecules25102448.
10
Elevated bone marrow sympathetic drive precedes systemic inflammation in angiotensin II hypertension.
Am J Physiol Heart Circ Physiol. 2019 Aug 1;317(2):H279-H289. doi: 10.1152/ajpheart.00510.2018. Epub 2019 May 31.
本文引用的文献
1
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16.
2
Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
Oncogene. 2018 Jan 18;37(3):313-322. doi: 10.1038/onc.2017.330. Epub 2017 Sep 18.
3
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2018 Jul;4(4):529-539. doi: 10.1016/j.euf.2017.01.004. Epub 2017 Jan 23.
4
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.
Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.
5
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.
Nat Commun. 2016 Nov 29;7:13668. doi: 10.1038/ncomms13668.
6
A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Prostate. 2016 Dec;76(16):1546-1559. doi: 10.1002/pros.23239. Epub 2016 Aug 16.
7
Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.
Cancer Res. 2016 Oct 1;76(19):5881-5893. doi: 10.1158/0008-5472.CAN-15-3372. Epub 2016 Aug 5.
8
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
Prostate. 2016 Dec;76(16):1484-1490. doi: 10.1002/pros.23232. Epub 2016 Jul 12.
9
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Sci Adv. 2016 Jun 24;2(6):e1501924. doi: 10.1126/sciadv.1501924. eCollection 2016 Jun.
10
EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor.
ACS Chem Biol. 2016 Sep 16;11(9):2499-505. doi: 10.1021/acschembio.6b00182. Epub 2016 Jul 14.
Zotero 插件